CuraMiss has secured 10 billion KRW in a Series A funding round to accelerate the clinical development of its stem cell therapy aimed at treating Duchenne muscular dystrophy.

Target Information

CuraMiss, a company specializing in the development of stem cell drugs with cell fusion capabilities, has successfully raised 10 billion KRW (approximately 8.5 million USD) in a Series A funding round. The secured funds will expedite the clinical development of a stem cell drug targeting Duchenne muscular dystrophy (DMD), a severe genetic condition that typically affects young boys, leading to progressive muscle degeneration.

The investment round, which was completed on the 15th of this month, saw participation from established financial investors including ID Ventures who engaged in follow-up investments, along with other venture capital firms such as DSC Investment, Schmitt, HB Investment, Hana Ventures, Union Investment Partners, and SNS Investment. A total of eight investors have aligned to support CuraMiss in its quest to innovate within the biopharmaceutical landscape.

Industry Overview in South Korea

The gene therapy market in South Korea has been gaining global attention, reflecting an increasing trend towards the development of advanced therapeutics. With significant investment efforts from both private and public sectors, the industr